Product
IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Aliases
IL13 [EQ]BBzeta/truncated CD19[t]+ Naive and Memory T Cells, IL13 [EQ]BBzeta/truncated CD19[t]+ TN/MEM Cells, IL13Ra2-specific-hinge-optimized-4-1BB-CAR/truncated CD19-expressing Autologous TN/MEM Lymphocytes
3 clinical trials
24 indications
Indication
Malignant Solid NeoplasmIndication
Uveal melanomaIndication
MelanomaIndication
Neuroendocrine TumorsIndication
ParagangliomaIndication
PheochromocytomaIndication
Adrenocortical CancerIndication
Pancreatic Neuroendocrine TumorIndication
Thyroid CancerIndication
Breast CancerIndication
Adenocarcinoma of the LungIndication
Head and Neck Squamous Cell CarcinomaIndication
Metastatic Malignant Solid NeoplasmIndication
Metastatic MelanomaIndication
Stage IIIC Cutaneous Melanoma AJCC v8Indication
Cutaneous MelanomaIndication
Recurrent Malignant Solid NeoplasmIndication
GlioblastomaIndication
Recurrent Malignant GliomaIndication
Recurrent WHO Grade II GliomaIndication
Recurrent WHO Grade III GliomaIndication
Malignant GliomaIndication
Refractory WHO Grade II GliomaIndication
Refractory WHO Grade III GliomaClinical trial
Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGliomaStatus: Active (not recruiting), Estimated PCD: 2023-12-18
Clinical trial
A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent GlioblastomaStatus: Recruiting, Estimated PCD: 2024-07-31